| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4025932 | Ophthalmology | 2014 | 12 Pages |
Abstract
Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Juan E. MD, Ebenezer MBBS, MD, Jiayan MS, Gui-shuang PhD, Maureen G. PhD, Cynthia A. MD, Glenn J. MD, Stuart L. MD, Barbara MD, Michael L. MD, Alison A. Martin, Stephanie A. PhD, Daniel F. MD, CATT Research Group CATT Research Group,